Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation

negativeNavacaprantNegative

AI Analysis

Summary

Neumora Therapeutics discontinued its Navacaprant program, resulting in a reduction in the company's fair value estimate. The decision negatively impacts the company's pipeline and investor outlook.

Outcome Details

Navacaprant discontinuation

Importance:6/10

Sentiment:

-0.80

drug discontinuationvaluation impactpipeline update

Related Companies

$NMRA

Read the original article

Published by yahoo_finance on July 11, 2026 3:08 PM

Read Original